Main news

                                    PRESS RELEASE OF THE CARDIOPROGRESS FOUNDATION

                  Main results of the XI International Forum

                     for Cardiology and Internal Medicine

Obesity and CVD: Launching the Heart Foundation's new clinical consensus statement
Obesity and CVD: Launching the Heart Foundation's new clinical consensus statement In Australia, about two-thirds of adults are overweight or obese, placing them at increased risk of cardiovascular disease (CVD) including coronary heart disease, heart failure, and arrhythmias. The Heart Foundation recently launched an Australian-first clinical consensus statement on obesity and CVD.


Simulation deficit in cardiology training: a missed opportunity for the modern trainee
Simulation deficit in cardiology training: a missed opportunity for the modern trainee Cardiology training today exists in a paradox. As the specialty becomes more complex, particularly in procedural domains, the time and resources available to train new cardiologists have dwindled. Simulation has become an increasingly important component of modern cardiology training, offering a safe, structured and reproducible environment in which clinical skills can be developed and refined.1 The term simulation encompasses a broad spectrum of educational approaches, ranging from focused task training to high-fidelity scenario-based learning.


Editorial Activity

cardiology book

International Research in Cardiology 2010-2014
International Research in Cardiology 2010-2014 Dear colleagues!
The Cardioprogress Foundation presents the book «International Research in Cardiology», which includes the results of the most important international clinical trials presented in 2010-2024. The authors systematized studies in 21 sections, which include risk factors, antiplatelet and anticoagulant therapy, laboratory and instrumental diagnostics, arrhythmia, invasive cardiology, valvular heart diseases, intensive care in cardiology and more.


New Drug Combos Could Cut Heart Failure Mortality by 60%
New Drug Combos Could Cut Heart Failure Mortality by 60% Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference.


Dedicated to eternal memory
Dedicated to eternal memory Dear colleagues!
On these holidays, the Cardioprogress Foundation remembers the heroes of the Great Patriotic War, whose feat was immortalized in the hearts of their descendants.


Spanish Cardiologists Release Gender-Specific CV Guide
Spanish Cardiologists Release Gender-Specific CV Guide The Spanish Society of Cardiology (SEC) Working Group on Women and Cardiovascular Diseases (SEC-GT CVD in Women) and the Association of Preventive Cardiology have convened an interdisciplinary group of experts from various Spanish societies and associations issued SEC-approved clinical guidelines published in the English-language edition of the Revista Española de Cardiología journal, which is designed to help medical professionals. in the diagnosis and treatment of cardiovascular diseases in women, paying special attention to gender differences.


Risk Model Validates Finerenone Effect in Heart Failure
Risk Model Validates Finerenone Effect in Heart Failure The Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction (PREDICT-HFpEF) tool effectively stratified cardiovascular risk, with risk being higher in the highest than in the lowest score quintile. Finerenone was consistently effective across risk levels in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), with a large absolute benefit observed in high-risk patients.


Muslim fasting from a medical point of view
Muslim fasting from a medical point of view Dear colleagues!
We offer you an article by Professor Mekhman N. Mamedov about medical aspects of muslim fasting and practical advice for applicants.


Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. Bill is developing a new therapeutic approach targeting CXCR3 for the treatment of myocarditis with immunotherapy.


Ross Procedure Making a Comeback in Aortic Valve Disease
Ross Procedure Making a Comeback in Aortic Valve Disease The Ross procedure, which can be used to treat young people with severe aortic valve disease, has seen wide swings in popularity over the years, but now, with consistent data on long-term survival and valve durability, numbers are steadily climbing again.